FoxO1 serves a necessary function in HDAC inhibitor‐based suppression of larynx carcinoma invasion and metastasis by blocking MMP7 (Ding et al., 2014) or by binding the ZEB2 promoter and reversing ZEB2‐induced EMT (Dong et al., 2017). Here, FOXO1 is linked to laryngeal carcinoma.